Local delivery of checkpoints antibodies.
Immune checkpoint inhibitors (ICI) based cancer immunotherapy has recently attracted considerable interest in the field of cancer therapy. The relevant immunotherapeutic agents do not directly attack the tumor, but boost the body's immune system to recognize and kill cancer cells. In this commentary, recent efforts utilizing immunoengineering for local delivery of these immune checkpoint antibodies are introduced. Future opportunities and challenges in this research theme are also commented.
a Joint Department of Biomedical Engineering , University of North Carolina at Chapel Hill and North Carolina State University , Raleigh , NC , USA.|b Division of Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill , Chapel Hill , NC , USA.
Chao
C
Wang
a Joint Department of Biomedical Engineering , University of North Carolina at Chapel Hill and North Carolina State University , Raleigh , NC , USA.|b Division of Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill , Chapel Hill , NC , USA.
Yanqi
Y
Ye
a Joint Department of Biomedical Engineering , University of North Carolina at Chapel Hill and North Carolina State University , Raleigh , NC , USA.|b Division of Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill , Chapel Hill , NC , USA.|c Department of Medicine University of North Carolina School of Medicine Chapel Hill , NC , USA.
Zhen
Z
Gu
D000906:Antibodies / Q000008:administration & dosage*; D035843:Biomedical Research / Q000639:trends; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage*; D007167:Immunotherapy / Q000379:methods*; D058990:Molecular Targeted Therapy / Q000379:methods; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy*
D000906:Antibodies; D007155:Immunologic Factors
biomaterials; cancer immunotherapy; drug delivery; immune checkpoint inhibitors; microneedle
Lancet. 2016 May 7;387(10031):1909-20
26952546
Expert Opin Drug Deliv. 2014 Nov;11(11):1769-80
25020088
Sci Transl Med. 2016 Mar 2;8(328):328rv4
26936508
Adv Drug Deliv Rev. 2016 Mar 1;98 :19-34
26546751
Nat Rev Clin Oncol. 2016 Feb;13(2):77-8
26787285
Nat Rev Drug Discov. 2015 Aug;14(8):561-84
26228759
Nat Med. 2010 Aug;16(8):915-20
20639891
Cell. 2016 Apr 7;165(2):272-5
27058661
Proc Natl Acad Sci U S A. 2015 Jul 7;112(27):8260-5
26100900
N Engl J Med. 2015 May 21;372(21):2006-17
25891304
Science. 2015 Apr 3;348(6230):56-61
25838373
Nat Rev Cancer. 2016 Jan;16(1):56-66
26694936
Nat Rev Clin Oncol. 2016 Aug;13(8):473-86
27141885
Proc Natl Acad Sci U S A. 2015 Nov 24;112(47):14467-72
26598681
Cell. 2015 Apr 9;161(2):201-4
25860604
PLoS One. 2015 Mar 18;10(3):e0120797
25785935
N Engl J Med. 2015 Jan 22;372(4):320-30
25399552
Adv Drug Deliv Rev. 2012 Nov;64(14):1547-68
22575858
Nano Lett. 2016 Apr 13;16(4):2334-40
26999507
N Engl J Med. 2015 Jun 25;372(26):2521-32
25891173
Biomater Sci. 2015 Jul;3(7):1018-24
26221936
Adv Mater. 2016 Apr;28(16):3115-21
26928976
Trends Cancer. 2016 Jun;2(6):286-294
27774519
Diabetes Care. 2015 Sep;38(9):e137-8
26116720
Ann Oncol. 2015 Dec;26(12):2375-91
26371282
J Am Chem Soc. 2014 Oct 22;136(42):14722-5
25336272
Angew Chem Int Ed Engl. 2015 Oct 5;54(41):12029-33
26310292
N Engl J Med. 2015 Jul 2;373(1):23-34
26027431
Trends Immunol. 2016 Jun;37(6):354-63
27105824
Adv Mater. 2016 Oct;28(40):8912-8920
27558441
Nature. 2016 Aug 4;536(7614):91-5
27350335
Immunity. 2016 Jun 21;44(6):1255-69
27332730
J Clin Invest. 2015 Sep;125(9):3384-91
26325035